Events - 2018 Gastrointestinal Cancers Symposium

Jan 2018
Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Jan 2018
Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Event Overview:

Register for the Gastrointestinal Cancers Symposium and join us for three days of translational research, novel clinical therapies, and state-of-the-art science in GI oncology.

The Gastrointestinal (GI) Cancers Symposium is a specialized oncology event designed to provide scientific and educational content for members of the GI cancer care and research community. This three-day meeting encompasses the latest science in cancers of the esophagus and stomach; the pancreas, small bowel, and hepatobiliary tract; and the colon, rectum, and anus. This year’s Symposium offers new breakout sessions covering cutting-edge and controversial topics, a networking luncheon for early-career oncologists, and the opportunity to view and discuss selected posters with respected faculty members during poster walks.

Exhibitor Information:

The exhibits at the Gastrointestinal Cancers Symposium highlight the most advanced treatments, products, and services in oncology and provide attendees the opportunity to meet with representatives from the healthcare industry, including pharmaceutical companies and advocacy groups.

About ASCO:

Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.

ASCO Promotes and Provides For

    Lifelong learning for oncology professionals,
    Cancer research,
    An improved environment for oncology practice,
    Access to quality cancer care,
    A global network of oncology expertise, and
    Educated and informed patients with cancer.

ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer.

Jan 18

7:00 AM-8:00 AM	Complimentary Continental Breakfast
7:00 AM-6:30 PM	Exhibits Open
7:50 AM-9:30 AM	Welcome and General Session 1: Response Assessment and Individualization of Management of Esophageal Adenocarcinoma (ARS) Sarah E. Hoffe, MD - Chair H. Lee Moffitt Cancer Center and Research Institute Gail Elizabeth Darling, MD - Chair University of Toronto Laura A. Dawson, MD Princess Margaret Cancer Centre Welcome of the Day Case Presentation Kenneth Wang, MD Mayo Clinic Initial Staging and Response Assessment Debate: Management of Esophageal Adenocarcinoma After Neoadjuvant Therapy With Complete Clinical Response—Surgery Versus Watchful Waiting Andrew Barbour, MBBS, PhD, FRACS, FACS University of Queensland Surgeon Perspective Florence Huguet, MD, PhD Hôpital Tenon Radiation Oncologist Perspective David H. Ilson, MD, PhD Memorial Sloan Kettering Cancer Center Improving Esophageal Adenocarcinoma Outcomes: Future Directions Panel Question and Answer
9:30 AM-10:00 AM	Break
10:00 AM-11:30 AM	General Session 2: Global Outlook on Gastric Cancer Ulysses Ribeiro Jr., MD, PhD - Chair University of São Paulo Khaldoun Almhanna, MD, MPH - Chair Moffitt Cancer Center Global Perspectives on Surveillance, Risk Factors, and Management of Early Gastric Cancer Alexander G. Meining, MD Medical School of the University of Ulm European Perspective Paola Catherine Montenegro, MD Instituto Nacional de Enfermedades Neoplasicas South American Perspective Seiichiro Abe, MD National Cancer Center Hospital Asian Perspective Margaret Gulley, MD University of North Carolina School of Medicine Capitalizing on Epstein-Barr Virus to Better Classify, Treat, and Monitor Gastric Cancer Abstract 1: Long-term outcome of a randomized phase III trial exploring the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ≥ T3 resectable gastric cancer: CCOG 1102. First author: Daishi Morimoto, MD Panel Question and Answer
11:30 AM-1:00 PM	Poster Session A: Cancers of the Esophagus and Stomach With Complimentary Boxed Lunch
11:30 AM-1:00 PM	Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach
12:00 PM-1:00 PM	Trainee and Early-Career Networking Luncheon *For a full list of participating faculty, please visit the Trainee & Early-Career Networking Luncheon page*
1:00 PM-2:00 PM	Rapid-Fire Abstract Session: Cancers of the Esophagus and Stomach Sarah E. Hoffe, MD - Chair Moffitt Cancer Center Ulysses Ribeiro, Jr., MD, PhD - Chair University of Sao Paulo Abstract 6: Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus open transthoracic esophagectomy for resectable esophageal cancer: A randomized controlled trial. First author: Pieter van der Sluis, MD, PhD, Msc Question and Answer Abstract 91: A prospective multicenter trial of S-1 with lafutidine vs S-1 as adjuvant chemotherapy for gastric cancer in Japan: AEOLUS. First author: Nozomu Machida, MD, PhD Question and Answer Abstract 8: CYTO-CHIP: Cytoreductive surgery versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: A propensity-score analysis from BIG RENAPE and FREGAT working groups. First author: Pierre Emmanuel Bonnot, BA Question and Answer Abstract 9: Associations of PD-1 and PD-L1 expression with mismatch repair status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma. First author: Maria Svensson, MD, PhD Student Question and Answer
1:00 PM-2:00 PM	Breakout Session: Multidisciplinary Management of Less Common Gastroesophageal Tumors Shishir Maithel, MD, FACS - Chair Emory University Winship Cancer Institute Ronald P. DeMatteo, MD, FACS University of Pennsylvania Hospital Guidelines for Perioperative Imatinib Therapy for Gastrointestinal Stromal Tumors Field F. Willingham, MD, MPH Emory University School of Medicine Evaluation of Gastroesophageal Submucosal Lesions and Minimally Invasive Management Options Panel Question and Answer
1:00 PM-2:00 PM	Breakout Session: FLOT or Not—Perioperative Management for Gastric Cancer Salah-Eddin Al-Batran, MD Institute of Clinical Cancer Research, Krankenhaus Nordwest, UCT-University Cancer Center Pro Jaffer A. Ajani, MD University of Texas MD Anderson Cancer Center Con Panel Question and Answer
2:00 PM-2:15 PM	Break
2:15 PM-3:45 PM	Oral Abstract Session A: Cancers of the Esophagus and Stomach David H. Ilson, MD, PhD - Chair Memorial Sloan Kettering Cancer Center K. Robert Shen, MD - Chair Mayo Clinic Abstract 2: The impact of the chemoradiation to surgery interval on pathological complete response: Short and long-term overall survival in esophageal cancer patients. First author: Basem Azab, BA Abstract 3: Impact of lung and heart dose on survival after radiotherapy for esophageal cancer. First author: Patrick Oh, BSc Theodore S. Hong, MD NSABP/ NRG Oncology/ Massachusetts General Hospital Discussion Abstract 4: Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial. First author: Florian Lordick, MD Late-Breaking Abstract Stephen Leong, MD University of Colorado Comprehensive Cancer Center Discussion Panel Question and Answer
3:45 PM-4:15 PM	Break
4:15 PM-5:30 PM	General Session 3: Is There a Role for Locoregional Therapies in Stage IV Esophageal and Gastric Cancers? (ARS) Paola Catherine Montenegro, MD - Chair Instituto Nacional de Enfermedades Neoplasicas Manisha Palta, MD - Chair Duke University Medical Center Case Presentation and Discussion Brian D. Badgwell, MD University of Texas MD Anderson Cancer Center Surgical Oncologist Perspective Elena Elimova, MD Princess Margaret Cancer Centre Medical Oncologist Perspective Maria A Hawkins, FRCR, MD, MRCP CRUK/MRC Oxford Institute for Radiation Oncology Radiation Oncologist Perspective
5:30 PM-6:30 PM	Poster Session A: Cancers of the Esophagus and Stomach With Complimentary Wine and Cheese Reception
5:30 PM-6:30 PM	Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach
5:45 PM-6:30 PM	Poster Walks Open to all attendees. Meet at the Poster Assistance Desk. Khaldoun Almhanna, MD, MPH Moffitt Cancer Center K. Robert Shen, MD Mayo Clinic

Jan 19

7:00 AM-8:00 AM	Complimentary Continental Breakfast
7:00 AM-6:30 PM	Exhibits Open
7:55 AM-9:30 AM	Welcome and General Session 4: Multimodality Management of Biliary Malignancies Shishir Maithel, MD, FACS - Chair Emory University Winship Cancer Institute Ryan Fields, MD, FACS - Chair Washington University School of Medicine in St. Louis Karyn A. Goodman, MD, MS University of Colorado Cancer Center Welcome of the Day Juan W. Valle, MD The Christie Hospital NHS Foundation Trust Current State of Adjuvant Therapy for Biliary Tract Malignancies Robin Kate Kelley, MD University of California San Francisco Advances in Molecular Targeted Therapies in Cholangiocarcinoma Charles Rosen, MD Mayo Clinic Liver Transplantation for Cholangiocarcinoma: Indications and Outcomes Panel Question and Answer
9:30 AM-10:00 AM	Break
10:00 AM-11:30 AM	General Session 5: Emerging Options for Hepatocellular Carcinoma—A Global Perspective Josep Llovet, MD, PhD - Chair Icahn School of Medicine at Mount Sinai Riccardo Lencioni, MD - Chair University of Miami Sylvester Comprehensive Cancer Center Massimo Colombo, MD Humanitas Research Hospital The Effect of New Antiviral Therapies for Hepatitis C on the Occurrence and Recurrence of Hepatocellular Carcinoma Richard K. G. Do, MD, PhD Memorial Sloan Kettering Cancer Center Diagnosis and Assessment of Response in Hepatocellular Carcinoma: LI-RADS, RECIST, and mRECIST Edward Kim, MD, FSIR Icahn School of Medicine at Mount Sinai Locoregional Therapy With Selective Internal Radiotherapy for Hepatocellular Carcinoma: Where Do We Stand? Jinsil Seong, MD, PhD Yonsei University College of Medicine Stereotactic Body Radiotherapy: What Role Does Focal Radiotherapy Play for Hepatocellular Carcinoma? Ann-Lii Cheng, MD, PhD National Taiwan University Hospital Systemic Therapy for Advanced Hepatocellular Carcinoma Panel Question and Answer
11:30 AM-1:00 PM	Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract With Complimentary Boxed Lunch
11:30 AM-1:00 PM	Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
12:00 PM-12:45 PM	Poster Walks Open to all attendees. Meet at the Poster Assistance Desk. Ryan Fields, MD, FACS Washington University School of Medicine in St. Louis Philip Agop Philip, MD, PhD, FRCP Karmanos Caner Institute
1:00 PM-2:00 PM	Rapid-Fire Abstract Session: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Jason C. Cheng, MD, MS, PhD - Chair National Taiwan University Hospital Shishir Maithel, MD, FACS - Chair Emory University Winship Cancer Institute Abstract 208: A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). First author: Ramesh Ramanathan, MD Question and Answer Abstract 209: KEYNOTE-224: Pembrolizumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib. First author: Andrew Zhu Question and Answer Abstract 210: Effect of transarterial chemoembolization plus external beam radiotherapy on survival of patients with hepatocellular carcinoma showing macroscopic vascular invasion compared with sorafenib: A randomized trial. First author: Sang Min Yoon Question and Answer Abstract 211: Genomics-driven precision medicine for advanced pancreatic ductal carcinoma (PDAC): Early results from the COMPASS trial (NCT02750657). First author: Kyaw Aung, MBBS, MRCP, PhD Question and Answer
1:00 PM-2:00 PM	Breakout Session: Hereditary Gastrointestinal Cancer Syndromes Aimee Lucas, MD, MS Icahn School of Medicine at Mount Sinai Genetic Syndromes Associated With Increased Risk of Pancreaticobiliary and Gastroduodenal Cancers Sonia Kupfer, MD University of Chicago Optimal Screening and Surveillance of Genetically High-Risk Individuals Flavio G. Rocha, MD Virginia Mason Hospital and Medical Center Surgical Management of Cancers in Patients with a Genetic Predisposition Panel Question and Answer
1:00 PM-2:00 PM	Breakout Session: Minimally Invasive Diagnostic and Interventional Techniques for Pancreaticobiliary Malignancies James Farrell, MD Yale School of Medicine, Yale University Technologic Advances in Endoscopic Visualization of Cancer Christopher J. Dimaio, MD Icahn School of Medicine at Mount Sinai Therapeutic Endoscopic Approaches to Pancreaticobiliary Tumors Shailesh V. Shrikhande, MD, MS, FRCS Tata Memorial Hospital Minimally Invasive Surgical Approaches: Current Evidence Panel Question and Answer
2:00 PM-2:15 PM	Break
2:15 PM-3:45 PM	Oral Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract Ryan Fields, MD, FACS - Chair Washington University School of Medicine in St. Louis Flavio G. Rocha, MD - Chair Virginia Mason Hospital and Medical Center Abstract 204: Phase II LAPACT Trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC). First author: Pascal Hammel Abstract 205: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113, FUGA-BT). First author: Chigusa Morizane, MD, PhD Brian M. Wolpin, MD Dana-Farber Cancer Institute Discussion Abstract 206: Randomized, Open Label, Multicenter, Phase II Trial comparing Transarterial Chemoembolization (TACE) plus Sorafenib with TACE Alone in Patients with Hepatocellular Carcinoma (HCC): TACTICS Trial. First author: Masatoshi Kudo, MD, PhD Abstract 207: Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase 3 CELESTIAL trial. First author: Ghassan Abou-Alfa, MD Jordi Bruix, MD, PhD University of Barcelona Discussion Panel Question and Answer
3:45 PM-4:15 PM	Break
4:15 PM-5:30 PM	General Session 6: Advanced and Metastatic Neuroendocrine Tumors (ARS) Philip Agop Philip, MD, PhD, FRCP - Chair Karmanos Cancer Institute Michelle Kang Kim, MD, PhD - Chair Icahn School of Medicine at Mount Sinai Case 1: Synchronous Metastatic Midgut Neuroendocrine Tumor Case 2: Gastric Neuroendocrine Tumor Case 3: Unresectable Pancreatic Neuroendocrine Massimo Falconi, MD Università Vita Salute - Ospedale San Raffaele Surgeon Perspective Marianne Pavel, MD Friedrich-Alexander University Erlangen-Nürnberg Endocrine/Oncology Perspective Parag Parikh, MD Washington University School of Medicine in St. Louis Radiation Oncologist Perspective Wolfgang Weber, MD Technical University of Munich Nuclear Medicine Perspective Michael C. Soulen, MD University of Pennsylvania Interventional Radiologist Perspective
5:30 PM-6:30 PM	Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract With Complimentary Wine and Cheese Reception
5:30 PM-6:30 PM	Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Jan 20

7:00 AM-7:55 AM	Rapid-Fire Abstract Session: Cancers of the Colon, Rectum, and Anus Michael J. Hall, MD, MS - Chair Fox Chase Cancer Center Abstract 557: Reverce: Randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, and irinotecan. First author: Kohei Shitara, MD Question and Answer Abstract 558: SCOT: Tumor sidedness and the influence of chemotherapy duration on DFS. First author: Mark Saunders, MD, PhD Question and Answer Abstract 559: Effect of physical activity trackers and daily text messages on quality-of-life in colorectal survivors (Smart Pace): A pilot randomized controlled trial. First author: Hilary Chan, BA Question and Answer Abstract 560: A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC). First author: Johanna Bendell, MD Question and Answer
7:00 AM-7:55 AM	Poster Session C: Cancers of the Colon, Rectum, and Anus
7:00 AM-7:55 AM	Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
7:00 AM-7:55 AM	Breakout Session: Intraperitoneal Chemotherapy for Intra-abdominal Malignancies Daniel Tandel Chang, MD - Chair Stanford University School of Medicine Debate: Colorectal Cancer With Peritoneal Metastasis—A Regional Disease Requiring Regional Therapy Edward Allen Levine, MD Wake Forest University Pro Garrett Michael Nash, MD, MPH Memorial Sloan Kettering Cancer Center Con Steven Arthur Ahrendt, MD University of Colorado School of Medicine Appendiceal Tumors and Peritoneal Mesotheliomas Panel Question and Answer
7:00 AM-7:55 AM	Breakout Session: Liquid Biopsies—Role in Management of Gastrointestinal Cancers Ash A. Alizadeh, MD, PhD Stanford Cancer Institute Overview of Technology: Circulating Tumor Cells and DNA Ryan Bruce Corcoran, MD, PhD Massachusetts General Hospital Clinical Implications of Liquid Biopsies Panel Question and Answer
7:00 AM-7:55 AM	Complimentary Continental Breakfast
7:55 AM-9:30 AM	Welcome and General Session 7: Early-Onset Colorectal Cancer Rodrigo Jover, MD, PhD - Chair Alicante University General Hospital Andrew T. Chan, MD, MPH - Chair Massachusetts General Hospital/ Harvard Medical School Shishir Maithel, MD, FACS Emory University Winship Cancer Institute Welcome of the Day Joseph J.Y. Sung, MD, PhD, MBBS The Chinese University of Hong Kong Epidemiology of Early-Onset Colon Cancer Fay Kastrinos, MD, MPH Columbia University Medical Center Health Disparities, Screening, and Prevention Irit Ben-Aharon, MD, PhD Davidoff Cancer Center Clinical Management and Survivorship Issues Abstract 552: Age distribution of tumor gene expression in patients with stage II/III colon cancer. First author: Howard Hochster, MD Panel Question and Answer
9:30 AM-10:00 AM	Break
10:00 AM-11:00 AM	Keynote Lecture: Mapping the Immune Landscape in Pancreatic Cancer Steven D. Leach, MD Dartmouth Norris Cotton Cancer Center
11:00 AM-12:30 PM	Oral Abstract Session C: Cancers of the Colon, Rectum, and Anus S. Gail Eckhardt, MD, FASCO - Chair University of Colorado School of Medicine Mary Uan-Sian Feng, MD - Chair University of California, San Francisco Abstract 553: Nivolumab + ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142. First author: Thierry Andre, MD Abstract 554: Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142. First author: Michael Overman, MD Zsofia Kinga Stadler, MD Memorial Sloan Kettering Cancer Center Discussion Abstract 555: Genetic profile of polyps and risk of advanced metachronous lesions. First author: Oscar Murcia Sr., MD Abstract 556: Prospective clinical study of circulating tumor cells for colorectal cancer screening. First author: Wen-Sy Tsai, MD, PhD Douglas Corley, MD, PhD, MPH Kaiser Permanente Discussion Panel Question and Answer
12:30 PM-2:00 PM	Poster Session C: Cancers of the Colon, Rectum, and Anus With Complimentary Boxed Lunch
12:30 PM-2:00 PM	Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
1:00 PM-1:45 PM	Poster Walks Open to all attendees. Meet at the Poster Assistance Desk. Andrea Cercek, MD Memorial Sloan Kettering Cancer Center TBD
2:00 PM-3:00 PM	General Session 8: Controversies in Adjuvant Therapy for Colorectal Cancer (ARS) Frank A. Sinicrope, MD - Chair Mayo Clinic Karyn A. Goodman, MD, MS - Chair University of Colorado Cancer Center Duration of Adjuvant Therapy for Colon Cancer: Is 3 Months Enough? Jeffrey A. Meyerhardt, MD, MPH, FASCO Dana-Farber Cancer Institute/ Partners Cancer Care U.S. Perspective Timothy Iveson, MD, FRCP University Hospital Southampton NHS Foundation Trust European Perspective Role of (Neo)Adjuvant Chemotherapy for Rectal Cancer: U.S. Versus European Approach Andrea Cercek, MD Memorial Sloan Kettering Cancer Center U.S. Perspective Cornelis J. H. Van De Velde, MD, PhD Leiden University Medical Center European Perspective Panel Question and Answer
3:00 PM-3:15 PM	Break
3:15 PM-4:30 PM	General Session 9: Contemporary Management of Colorectal Cancer Liver Metastases (ARS) Flavio G. Rocha, MD - Chair Virginia Mason Hospital and Medical Center Michael J. Hall, MD, MS - Chair Fox Chase Cancer Center Case Presentation and Discussion Guy A. Van Hazel, FRACP, FRCP, MBBS Sir Charles Gairdner Hospital Medical Oncologist Perspective Alejandra Méndez Romero, MD, PhD Erasmus Medical Center Radiation Oncologist Perspective Mark Hull, MD, PhD University of Leeds Clinician Scientist Perspective Rene Adam, MD, PhD Paul Brousse Hospital, France Surgeon Perspective